Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 6

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 6
---
 in an open label Phase II trial in metastatic castrate resistant prostate cancer. The Company enrolled
the first patient in this trial in in December 2023. The Company will report data from each cohort as it becomes available. Because
of the modified Bayesian design, the Company estimates the trial will be completely enrolled by the end of 2025 with top-line data expected
six months later. Topline data is divided into immunologic and tumor response variables. The most important immunologic response variable
is related to memory like NK cell persistence. This is how long are the number of mlNK cells in patients blood compared to baseline. There
are 3 important variables to tumor response: i) blood PSA changes; ii) change in PMSA scan and iii) change in circulating tumor DNA (ctDNA).
Ideally, the levels of all three variables decrease with treatment. We do not expect this 6-month trial to provide survival data.

Recent Developments

Phase 2 MINDFuL Trial Results for XPro

On June 30, 2025, the Company announced topline results from its Phase 2 MINDFuL trial evaluating
XPro for early AD. The trial did not meet its primary or key secondary endpoints in the modified intent-to-treat population (n=200). However,
in a pre-specified subgroup of patients with amyloid-positive AD and multiple inflammatory biomarkers (n=100), XPro demonstrated cognitive
and biomarker benefits, including improvements on EMACC and NPI-12, and reductions in plasma pTau217 and GFAP. XPro was well-tolerated
with no ARIA-E or ARIA-H observed. The Company plans to present full results at The Alzheimer’s Association International Conference
in July 2025 and intends to file for Breakthrough Therapy Designation and meet with the FDA to discuss a pivotal trial.

Financing Activities since March 31, 2025

Since April 1, 2025, the Company issued and sold 233,309 shares in April, 197,190 shares in May and 224,348 shares in June for aggregate gross proceeds of $5.0 million, pursuant to the Company’s “at-the-market” sales agreement with RBC Capital Markets LLC and BTIG, LLC.

Corporate Information

Our principal executive offices
are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432. Our telephone number is (561) 710-0512. We